ABSTRACT
A novel series of trans-1,3-cyclohexyl diamides was discovered and characterized as mGluR5 negative allosteric modulators (NAMs) lacking an alkyne moiety. Conformational constraint of one of the amide bonds in the diamide template led to a spirooxazoline template. A representative compound (24d) showed good in vitro potency, high CNS penetration and, upon subcutaneous dosing, demonstrated efficacy in the mouse marble burying test, generally used as indicative of potential anxiolytic activity.
Subject(s)
Amides/chemistry , Amides/pharmacology , Cyclohexanes/chemistry , Cyclohexanes/pharmacology , Receptor, Metabotropic Glutamate 5/chemistry , Allosteric Regulation , Amides/chemical synthesis , Amides/pharmacokinetics , Animals , Cyclohexanes/chemical synthesis , Cyclohexanes/pharmacokinetics , HEK293 Cells , Humans , Mice , Models, Molecular , Molecular Conformation , Receptor, Metabotropic Glutamate 5/metabolism , Structure-Activity RelationshipABSTRACT
Previous studies demonstrated that the Group III mGlu receptor-selective orthosteric agonist, LSP1-2111 produced anxiolytic- but not antidepressant-like effects upon peripheral administration. Herein, we report the pharmacological actions of Lu AF21934, a novel, selective, and brain-penetrant positive allosteric modulator (PAM) of the mGlu(4) receptor in the stress-induced hyperthermia (SIH), four-plate, marble-burying and Vogel's conflict tests. In all models, except Vogel's conflict test, a dose-dependent anxiolytic-like effect was seen. The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin. These results suggest that the GABAergic system, but not the serotonergic system, is involved in the mechanism of the anxiolytic-like phenotype of Lu AF21934 in rodents. Lu AF21934 did not produce antidepressant-like effects in the tail suspension test (TST) in mice; however, it decreased the basal locomotor activity of mice that were not habituated to activity cages. This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.
Subject(s)
Allosteric Regulation/physiology , Anilides/pharmacology , Anti-Anxiety Agents/pharmacology , Antidepressive Agents/pharmacology , Cyclohexanecarboxylic Acids/pharmacology , Receptors, Metabotropic Glutamate/physiology , Animals , Behavior, Animal/drug effects , Brain/drug effects , Brain/metabolism , Dose-Response Relationship, Drug , Flumazenil/pharmacology , GABA-A Receptor Antagonists/pharmacology , Male , Mice , Mice, Inbred C57BL , Motor Activity/drug effects , Piperazines/pharmacology , Pyridines/pharmacology , Rats , Rats, Wistar , Receptors, Metabotropic Glutamate/agonists , Ritanserin/pharmacology , Serotonin/metabolism , Serotonin Antagonists/pharmacologyABSTRACT
Group III metabotropic glutamate (mGlu) receptors are localized in presynaptic terminals within basal ganglia (BG) circuitry that become hyperactive due to dopamine depletion in Parkinson's disease (PD). For this reason, group III mGlu receptors, in particular mGlu4, have been considered as key strategic targets for non-dopaminergic pharmacological treatments aimed at modulating these synapses, without producing the well known side-effects of l-DOPA, in particular the highly disabling l-DOPA-induced dyskinesia (LID). Herein we add physiological and functional support to this hypothesis using Lu AF21934, a novel selective and brain-penetrant mGlu4 receptor positive allosteric modulator (PAM) tool compound. By in vitro electrophysiological recordings we demonstrate that Lu AF21934 inhibits corticostriatal synaptic transmission and enhances the effect of the orthosteric mGlu4 receptor-preferred agonist LSP1-2111. In naïve rats, Lu AF21934 dose-dependently (10 and 30 mg/kg) alleviated haloperidol-induced catalepsy. In hemiparkinsonian rats (unilateral 6-hydroxydopamine lesion of the substantia nigra pars compacta), Lu AF21934 alone did not affect akinesia at the doses tested (10 and 30 mg/kg). However, when Lu AF21934 was combined with sub-threshold doses of l-DOPA (1 and 5 mg/kg), it acted synergistically in alleviating akinesia in a dose-dependent manner and, notably, also reduced the incidence of LID but not its severity. Interestingly, these effects occurred at Lu AF21934 brain free concentrations that showed functional activity in in vitro screens (calcium flux and electrophysiology assays). These results support the potential for antiparkinsonian clinical use of a combined treatment consisting in l-DOPA and a mGlu4 receptor PAM to reduce efficacious l-DOPA doses (generally known as l-DOPA sparing), while maintaining the same benefit on PD motor troubles, and at the same time minimizing the development of LID. This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.
Subject(s)
Allosteric Regulation/physiology , Anilides/pharmacology , Cyclohexanecarboxylic Acids/pharmacology , Dyskinesia, Drug-Induced/drug therapy , Excitatory Amino Acid Agonists/pharmacology , Levodopa/pharmacology , Parkinson Disease/drug therapy , Receptors, Metabotropic Glutamate/agonists , Allosteric Regulation/drug effects , Aminobutyrates/agonists , Aminobutyrates/pharmacology , Aminobutyrates/therapeutic use , Anilides/pharmacokinetics , Anilides/therapeutic use , Animals , Catalepsy/chemically induced , Catalepsy/drug therapy , Cyclohexanecarboxylic Acids/pharmacokinetics , Cyclohexanecarboxylic Acids/therapeutic use , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Synergism , Excitatory Amino Acid Agonists/pharmacokinetics , Excitatory Amino Acid Agonists/therapeutic use , Excitatory Postsynaptic Potentials/drug effects , Excitatory Postsynaptic Potentials/physiology , Haloperidol/antagonists & inhibitors , Haloperidol/pharmacology , Levodopa/adverse effects , Levodopa/therapeutic use , Male , Oxidopamine , Phosphinic Acids/agonists , Phosphinic Acids/pharmacology , Phosphinic Acids/therapeutic use , Rats , Rats, Sprague-Dawley , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Receptors, Metabotropic Glutamate/physiology , Synaptic Transmission/drug effects , Synaptic Transmission/physiologyABSTRACT
4-(1-Phenyl-1H-pyrazol-4-yl)quinoline (1) was identified by screening the Lundbeck compound collection, and characterized as having mGlu4 receptor positive allosteric modulator properties. Compound 1 is selective over other mGlu receptors and a panel of GPCRs, ion channels and enzymes, but has suboptimal lipophilicity and high plasma and brain non-specific binding. In view of the challenges at the hit-to-lead stage previously reported in the development of mGlu4 receptor positive allosteric modulators (PAMs), a thorough structure-mGlu4 PAM activity relationship study was conducted to interrogate the chemical tractability of this chemotype. The central pyrazole ring tolerates the addition of one or two methyl groups. The C-7 position of the quinoline ring provides a site tolerant to hydrophilic substituents, enabling the design of diverse analogs with good in vitro mGlu4 PAM potency and efficacy, as well as improved microsomal turnover in vitro, compared to 1. In spite of the excellent ligand efficiency of 1 (LE=0.43), optimization of in vitro potency for this series reached a plateau around EC(50)=200 nM.
Subject(s)
Allosteric Regulation , Quinolines/pharmacology , Receptors, Metabotropic Glutamate/drug effects , Animals , Brain/metabolism , Drug Evaluation, Preclinical/methods , Rats , Structure-Activity RelationshipABSTRACT
A series of compounds based on the mGluR5-selective ligand 2-methyl-6-(phenylethynyl)pyridine (MPEP) were designed and synthesized. The compounds were found to be either structural analogues of MPEP, substituted monomers, or dimeric analogues. All compounds retained mGluR5 selectivity with only weak or no activity at other mGluRs or iGluRs. The substituted analogue, 1,3-bis(pyridin-2-ylethynyl)benzene (19), is a potent negative modulator at mGluR5, whereas all other compounds lost potency relative to MPEP and showed that activity is highly dependent on the position of the nitrogen atom in the pyridine moieties. A homology modeling and ligand docking study was used to understand the binding mode and the observed selectivity of compound 19.
Subject(s)
Alkynes/chemical synthesis , Anti-Anxiety Agents/chemical synthesis , Anxiety Disorders/drug therapy , Pyridines/chemical synthesis , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Alkynes/pharmacology , Alkynes/therapeutic use , Allosteric Regulation , Amino Acid Sequence , Animals , Anti-Anxiety Agents/pharmacology , Anti-Anxiety Agents/therapeutic use , Anxiety Disorders/metabolism , Binding Sites , Brain/drug effects , Brain/metabolism , CHO Cells , Cricetinae , Dimerization , Glutamic Acid/metabolism , Humans , Models, Molecular , Molecular Sequence Data , Protein Binding , Pyridines/pharmacology , Pyridines/therapeutic use , Receptor, Metabotropic Glutamate 5 , Receptors, Metabotropic Glutamate/metabolism , Structure-Activity RelationshipABSTRACT
A series of 6-aryl-3-pyrrolidinylpyridine analogs was explored as structurally novel negative allosteric modulators of the mGlu5 receptor lacking an alkyne or oxadiazole moiety. Compounds in this series were characterized by tractable SAR, good in vitro potencies and brain penetration in rodents.
Subject(s)
Pyridines/pharmacology , Pyrrolidines/pharmacology , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Animals , Dose-Response Relationship, Drug , HEK293 Cells , Humans , Models, Molecular , Molecular Structure , Pyridines/chemical synthesis , Pyridines/chemistry , Pyrrolidines/chemical synthesis , Pyrrolidines/chemistry , Rats , Rats, Sprague-Dawley , Receptor, Metabotropic Glutamate 5 , Receptors, Metabotropic Glutamate/blood , Stereoisomerism , Structure-Activity RelationshipABSTRACT
There is an increasing amount of evidence to support that activation of the metabotropic glutamate receptor 4 (mGlu4 receptor), either with an orthosteric agonist or a positive allosteric modulator (PAM), provides impactful interventions in diseases such as Parkinson's disease, anxiety, and pain. mGlu4 PAMs may have several advantages over mGlu4 agonists for a number of reasons. As part of our efforts in identifying therapeutics for central nervous system (CNS) diseases such as Parkinson's disease, we have been focusing on metabotropic glutamate receptors. Herein we report our studies with a series of tricyclic thiazolopyrazoles as mGlu4 PAMs.
Subject(s)
Central Nervous System Agents/chemical synthesis , Heterocyclic Compounds, 3-Ring/chemical synthesis , Pyrazoles/chemical synthesis , Receptors, Metabotropic Glutamate/physiology , Allosteric Regulation , Animals , Aza Compounds/chemical synthesis , Aza Compounds/chemistry , Aza Compounds/pharmacology , Azulenes/chemical synthesis , Azulenes/chemistry , Azulenes/pharmacology , Brain/metabolism , Cell Line , Central Nervous System Agents/chemistry , Central Nervous System Agents/pharmacology , ERG1 Potassium Channel , Ether-A-Go-Go Potassium Channels/antagonists & inhibitors , Heterocyclic Compounds, 3-Ring/chemistry , Heterocyclic Compounds, 3-Ring/pharmacology , Humans , In Vitro Techniques , Indazoles/chemical synthesis , Indazoles/chemistry , Indazoles/pharmacology , Mice , Microsomes, Liver/metabolism , Models, Molecular , Permeability , Pyrazoles/chemistry , Pyrazoles/pharmacology , Pyridines/chemical synthesis , Pyridines/chemistry , Pyridines/pharmacology , Rats , Stereoisomerism , Structure-Activity RelationshipABSTRACT
A luminescence assay using a new plate reader, the LumiLux (PerkinElmer, Waltham, MA), has been validated for high-throughput screening (HTS). In this study, we compared the aequorin luminescence-based calcium mobilization assay to the fluorescence-based calcium assay. A cell line stably co-expressing apo-aequorin, a chimeric G-protein, and a G-protein-coupled dopamine receptor was used to screen a collection of 8,106 compounds using the Hamamatsu Photonics (Bridgewater, NJ) FDSS6000 and LumiLux as the plate readers. The assay parameters evaluated included hit rate correlation, signal-to-noise ratio, and overall assay performance calculated by Z and standard deviation. The average Z values and hit rates were comparable between assay platforms;however, the standard deviation for the agonist aequorin assay was significantly smaller. There was also a significant decrease in the number of false-positives with the aequorin assay. These results suggest that the aequorin assay in combination with the new plate reader, LumiLux, provides a simple, cost-effective, robust, and sensitive assay for HTS
Subject(s)
Aequorin/chemistry , Calcium/analysis , Drug Evaluation, Preclinical/methods , Luminescent Agents/chemistry , Luminescent Measurements/methods , Receptors, Calcium-Sensing/analysis , Aniline Compounds/chemistry , Animals , Apoproteins/analysis , Apoproteins/chemistry , CHO Cells , Calcium/metabolism , Cluster Analysis , Cricetinae , Cricetulus , Dopamine Antagonists/analysis , Dopamine Antagonists/classification , Dopamine Antagonists/pharmacology , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/economics , False Positive Reactions , Fluorescence , Fluorescent Dyes/chemistry , Imidazoles/chemistry , Inhibitory Concentration 50 , Kinetics , Luminescent Measurements/economics , Pyrazines/chemistry , Receptors, Calcium-Sensing/metabolism , Receptors, Dopamine , Robotics/economics , Software , Xanthenes/chemistryABSTRACT
The alpha1D-adrenergic receptor (alpha1D-AR) is a G protein-coupled receptor (GPCR) that is poorly trafficked to the cell surface and largely nonfunctional when heterologously expressed by itself in a variety of cell types. We screened a library of approximately 30 other group I GPCRs in a quantitative luminometer assay for the ability to promote alpha1D-AR cell surface expression. Strikingly, these screens revealed only two receptors capable of inducing robust increases in the amount of alpha1D-AR at the cell surface: alpha1B-AR and beta2-AR. Confocal imaging confirmed that coexpression with beta2-AR resulted in translocation of alpha1D-AR from intracellular sites to the plasma membrane. Additionally, coimmunoprecipitation studies demonstrated that alpha1D-AR and beta2-AR specifically interact to form heterodimers when coexpressed in HEK-293 cells. Ligand binding studies revealed an increase in total alpha1D-AR binding sites upon coexpression with beta2-AR, but no apparent effect on the pharmacological properties of the receptors. In functional studies, coexpression with beta2-AR significantly enhanced the coupling of alpha1D-AR to norepinephrine-stimulated Ca2+ mobilization. Heterodimerization of beta2-AR with alpha1D-AR also conferred the ability of alpha1D-AR to cointernalize upon beta2-AR agonist stimulation, revealing a novel mechanism by which these different adrenergic receptor subtypes may regulate each other's activity. These findings demonstrate that the selective association of alpha1D-AR with other receptors is crucial for receptor surface expression and function and also shed light on a novel mechanism of cross talk between alpha1- and beta2-ARs that is mediated through heterodimerization and cross-internalization.
Subject(s)
Receptors, Adrenergic, alpha-1/physiology , Receptors, Adrenergic, beta-2/physiology , Receptors, Cell Surface/metabolism , Adrenergic beta-Agonists/pharmacology , Albuterol/pharmacology , Blotting, Western , Calcium/metabolism , Cell Line , Humans , Immunoprecipitation , Microscopy, Confocal , Plasmids/genetics , Radioligand Assay , Receptors, Adrenergic, alpha-1/biosynthesis , Receptors, Adrenergic, alpha-1/genetics , Receptors, Adrenergic, beta-2/genetics , Receptors, G-Protein-Coupled/metabolismABSTRACT
Olfactory receptors (ORs) comprise more than half of the large class I G protein-coupled receptor (GPCR) superfamily. Although cloned over a decade ago, little is known about their properties because wild-type ORs do not efficiently reach the cell surface following heterologous expression. Receptor-receptor interactions strongly influence surface trafficking of other GPCRs, and we examined whether a similar mechanism might be involved in OR surface expression. Olfactory neurons are known to express beta-adrenergic receptors (ARs), and we found that coexpression with beta(2)-ARs, but not any other AR subtypes, dramatically increased mouse 71 (M71) OR surface expression in human embryonic kidney 293 cells. A persistent physical interaction between M71 ORs and beta(2)-ARs was shown by coimmunoprecipitation and by cointernalization of the two receptors in response to their specific ligands. Also, coexpression of wild-type M71 ORs with beta(2)-ARs resulted in cAMP responses to the M71 ligand acetophenone. Finally, in situ hybridization studies showed extensive colocalization of M71 OR and beta(2)-AR expression in mouse olfactory epithelium. These data demonstrate the successful heterologous surface expression of a functional wild-type OR and reveal that persistent physical association with other GPCRs can control OR surface expression.
Subject(s)
Gene Expression Regulation , Receptors, Adrenergic, beta-2/genetics , Receptors, Adrenergic, beta-2/metabolism , Receptors, Odorant/genetics , Receptors, Odorant/metabolism , Adrenergic beta-2 Receptor Agonists , Animals , Cell Line , Cell Membrane/metabolism , Endocytosis , Epithelium/metabolism , Humans , Mice , Microscopy, Confocal , Protein Binding , Protein Transport , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Odorant/agonistsABSTRACT
alpha(1)-Adrenergic receptors (ARs) belong to the large Class I G protein-coupled receptor superfamily and comprise three subtypes (alpha(1A), alpha(1B), and alpha(1D)). Previous work with heterologously expressed C-terminal green fluorescent protein (GFP)-tagged alpha(1)-ARs showed that alpha(1A)- and alpha(1B)-ARs localize to the plasma membrane, whereas alpha(1D)-ARs accumulate intracellularly. We recently showed that alpha(1D)- and alpha(1B)-ARs form heterodimers, whereas alpha(1D)- and alpha(1A)-ARs do not. Here, we examined the role of heterodimerization in regulating alpha(1D)-AR localization using both confocal imaging of GFP- or CFP-tagged alpha(1)-ARs and a luminometer-based surface expression assay in HEK293 cells. Co-expression with alpha(1B)-ARs caused alpha(1D)-ARs to quantitatively translocate to the cell surface, but co-expression with alpha(1A)-ARs did not. Truncation of the alpha(1B)-AR extracellular N terminus or intracellular C terminus had no effect on surface expression of alpha(1D)-ARs, suggesting primary involvement of the hydrophobic core. Co-transfection with an uncoupled mutant alpha(1B)-AR (Delta12alpha(1B)) increased both alpha(1D)-AR surface expression and coupling to norepinephrine-stimulated Ca(2+) mobilization. Finally, GFP-tagged alpha(1D)-ARs were not detected on the cell surface when expressed in rat aortic smooth muscle cells that express no endogenous ARs, but were almost exclusively localized on the surface when expressed in DDT(1)MF-2 cells, which express endogenous alpha(1B)-ARs. These studies demonstrate that alpha(1B)/alpha(1D)-AR heterodimerization controls surface expression and functional coupling of alpha(1D)-ARs, the N- and C-terminal domains are not involved in this interaction, and that alpha(1B)-AR G protein coupling is not required. These observations may be relevant to many other Class I G protein-coupled receptors, where the functional consequences of heterodimerization are still poorly understood.
Subject(s)
Cell Membrane/metabolism , Receptors, Adrenergic, alpha-1/biosynthesis , Amino Acid Sequence , Animals , Calcium/metabolism , Cell Line , Cricetinae , Dimerization , Green Fluorescent Proteins , Humans , Inositol Phosphates/chemistry , Luminescent Proteins/metabolism , Microscopy, Confocal , Microscopy, Fluorescence , Molecular Sequence Data , Muscle, Smooth/cytology , Protein Structure, Tertiary , Protein Transport , Rats , Recombinant Fusion Proteins/metabolism , TransfectionABSTRACT
The potential role of dimerization in controlling the expression and pharmacological properties of alpha1-adrenoceptor subtypes was examined using coimmunoprecipitation of epitope-tagged receptors. Human alpha1-adrenoceptor subtypes (alpha1A, alpha1B, alpha1D) were tagged at their amino-termini with Flag or hemagglutinin epitopes and transfected into human embryonic kidney 293 cells. Homodimerization of all three subtypes was observed by coimmunoprecipitation of receptors with different tags and was not altered by norepinephrine treatment. Heterodimer formation between hemagglutinin-tagged alpha1B-adrenoceptors and Flag-tagged alpha1A- or alpha1D-adrenoceptors was also observed. However, no alpha1A/alpha1D-adrenoceptor heterodimers were observed, suggesting that dimerization is subtype-specific. The extent of heterodimerization was also unaltered by norepinephrine treatment. alpha1-Adrenoceptor truncation mutants lacking carboxyl or amino-terminal sequences formed homo- and heterodimers similarly to full-length receptors, suggesting that these domains play little or no role in dimerization. Biotinylation with a membrane-impermeable agent showed that monomers and homo- and hetero-oligomers of all three subtypes are expressed on the cell surface. Radioligand binding studies showed that heterodimerization did not alter the affinity of alpha1-adrenoceptors for norepinephrine, prazosin, or subtype-selective antagonists, suggesting that dimerization does not result in pharmacologically distinct subtypes. However, coexpression of alpha1B-adrenoceptors significantly increased both binding site density and protein expression of alpha1A- and alpha1D-adrenoceptors, and increased cell surface expression of alpha1D-adrenoceptors, suggesting a functional role for heterodimerization. Conversely, coexpression of alpha1A-with alpha1D-adrenoceptors, which did not heterodimerize, had no effect on receptor density or protein. These studies demonstrate subtype-selective heterodimerization of alpha1-adrenoceptors, which does not change their pharmacological properties but seems to have functional consequences in regulating receptor expression and trafficking.
Subject(s)
Receptors, Adrenergic, alpha-1/classification , Receptors, Adrenergic, alpha-1/physiology , Adrenergic alpha-Antagonists/metabolism , Adrenergic alpha-Antagonists/pharmacology , Cell Line , Dimerization , Dose-Response Relationship, Drug , Humans , Protein Isoforms/biosynthesis , Protein Isoforms/classification , Protein Isoforms/metabolism , Protein Isoforms/physiology , Receptors, Adrenergic, alpha-1/biosynthesis , Receptors, Adrenergic, alpha-1/metabolismABSTRACT
The formation of coenzyme A thioesters from long-chain fatty acids represents a metabolic branch point. We have isolated, cloned and sequenced a long-chain fatty acyl CoA synthetase (LCFACoAS) that is localized to the endothelium of rabbit heart and aorta. Immunofluoresence and in situ hybridization studies show intense staining of the intimal layer of the aorta and coronary vessels. The microvessels, including the capillaries, of the coronary circulation also show intense immunofluoresence. The enzyme shares only about 30% to 70% homology with the primary amino acid sequence of the other known LCFACoAS. There is a region of 44 amino acids at the carboxy terminus, which is unique to the vascular enzyme. This domain contains the most hydrophobic region of the molecule, indicating that it may function as a membrane anchoring site. These results suggest that this LCFACoAS represents a novel isoform, whose functional significance remains to be determined.
Subject(s)
Acyl Coenzyme A/genetics , Aorta/enzymology , Endothelium, Vascular/enzymology , Acyl Coenzyme A/analysis , Acyl Coenzyme A/isolation & purification , Amino Acid Sequence , Animals , Base Sequence , Blotting, Northern , Coronary Vessels/enzymology , DNA, Complementary/biosynthesis , DNA, Complementary/chemistry , Hydrophobic and Hydrophilic Interactions , Immunohistochemistry , In Situ Hybridization , Microsomes, Liver/enzymology , Molecular Sequence Data , Molecular Weight , Precipitin Tests , RNA, Messenger/analysis , Rabbits , Sequence AlignmentABSTRACT
The role of the N-terminus of human alpha(1D)-adrenoceptors was examined by deleting the first 79 amino acids (Delta(1-79)) and epitope-tagging to facilitate immunoprecipitation and detection. Following transfection into HEK293 cells, 6- to 13-fold increases in the density of specific [125I]BE 2254 binding sites were observed for both tagged and untagged Delta(1-79)alpha(1D)- compared to full-length alpha(1D)-adrenoceptors, while agonist and antagonist affinities remained unchanged. In contrast, immunoprecipitation of tagged receptors showed that full-length alpha(1D)-adrenoceptor protein was at least twice as abundant as Delta(1-79)alpha(1D)-adrenoceptor protein. Photoaffinity labelling with [125I]arylazidoprazosin showed much more intense labelling of tagged Delta(1-79)alpha(1D)- than of full-length alpha(1D)-adrenoceptors. Substantial N-linked glycosylation of tagged Delta(1-79)alpha(1D)-adrenoceptors was observed, although full-length alpha(1D)-adrenoceptors contain two consensus glycosylation sites but are not glycosylated. These results suggest that N-terminal truncation of alpha(1D)-adrenoceptors enhances processing of a binding competent form in HEK293 cells; and show a clear dissociation between abundance of receptor protein and density of receptor binding sites.